Hepatology
Conference Coverage
NAFLD less common, more severe in black children
ORLANDO – Overall prevalence in obese kids: 42%
From the Journals
AGA Clinical Practice Update: Statins are safe, effective, and important for most patients with liver disease and dyslipidemia
With a few exceptions, patients with liver disease should receive lipid-lowering agents at full dose.
Applied Evidence
How best to manage chronic cholestasis
Here's how to maximize your use of lab work and imaging techniques to identify the source of your patient's cholestasis and provide prompt...
From the Journals
Insurer denials of DAA therapy for HCV on the rise
About one in three patients had lack of fill approval by insurers.
Video
VIDEO: Hepatitis C eradication cuts nonliver cancer rate
WASHINGTON - U.S. data from thousands of treated hepatitis C patients implicates the virus as carcinogenic and a factor in a wide range of...
News
NAFLD patients with abnormal liver tests may not get statins when indicated
WASHINGTON – Abnormal liver tests can make providers hesitant to start statins in NAFLD patients.
From the Journals
Scoring system quantified chances of HCV treatment benefit
Does a new scoring system hold the promise of avoiding 'MELD purgatory'?
Conference Coverage
How to choose between highly effective HBV therapies
The newest drug, tenofovir alafenamide, has the edge in its safety profile for treating chronic hepatitis B infection.
Conference Coverage
Where the latest HCV drug combos fit in
MAUI, HAWAII – The biggest remaining challenge in the treatment of hepatitis C is to gain improved access to therapy, according to Steven L. Flamm...
From the Journals
Very few infants born to HCV-infected mothers receive testing
Despite increasing prevalence of hepatitis C virus infection in pregnant women, infants exposed to the disease are screened at a very low rate.
Conference Coverage
New drugs provide new options in HCC
PHILADELPHIA – “We are on the cusp where new compounds not only are being tested, but they are being approved.”